Pays: Malte
Langue: anglais
Source: Medicines Authority
ISONIAZID; RIFAMPICIN
Sanofi Malta Limited
J04AM02
ISONIAZID; RIFAMPICIN
COATED TABLET
ISONIAZID 150 mg; RIFAMPICIN 300 mg
POM
ANTIMYCOBACTERIALS
Authorised
2007-08-08
TURN OVER _I_ IMPORTANT THINGS YOU NEED TO KNOW ABOUT RIFINAH 300/150MG TABLETS The name of your medicine is Rifinah 300/150mg Coated Tablets (called Rifinah 300/150mg Tablets in this leaflet). • It is very important that you take Rifinah 300/150mg Tablets exactly as your doctor has told you. There is a chance of you having a severe and dangerous allergic reaction if you do not take your tablets every day as you are told • You must keep taking it until your doctor tells you to stop. • If you are taking any other medicines, including medicines you have bought from the pharmacy or shop, you must make sure your doctor knows • Rifinah 300/150mg Tablets makes all of your body fluids an orange or red colour. Do not worry - this is normal and not harmful • Take Rifinah 300/150mg Tablets on an empty stomach. This means at least 30 minutes before food or 2 hours after food • While you are taking Rifinah 300/150mg Tablets, you should not eat cheese, skipjack tuna or drink red wine (see ‘Taking Rifinah 300/150mg Tablets with food and drink’) • If you get a temperature, are sick, begin to feel more unwell, lose your appetite or have yellowing of the skin, gums or eyes, you must talk to your doctor straight away READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it to others. It may harm them, even if their symptoms are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Rifinah 300/150mg Tablets are and what they are used for 2. What you need to know before you take Rifinah 300/150mg Tablets 3. How to take Rifinah 300/150mg Tablets 4. Possible side effects 5. How to store Rifinah 300/150mg Tablets 6. Cont Lire le document complet
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Rifinah 300/150mg Coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances (per tablet): Rifampicin 300mg Isoniazid 150mg Excipients (per tablet): Sucrose 181.03mg E110, Sunset yellow 1.37mg For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Coated tablet Orange, smooth, shiny capsule shaped sugar coated tablet. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Rifinah is indicated in the treatment of all forms of tuberculosis, including fresh, advanced and chronic cases. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION For oral administration. Another antituberculosis drug may be given concurrently with Rifinah until the susceptibility of the infecting organism to rifampicin and isoniazid has been confirmed. _Adults:_ Patients should be given the following single daily dose preferably on an empty stomach at least 30 minutes before a meal or 2 hours after a meal: Rifinah 150: Patients weighing less than 50kg - 3 tablets. Rifinah 300: Patients weighing 50kg or more - 2 tablets. _Use in the elderly:_ Caution should be exercised in such patients especially if there is evidence of liver impairment. 4.3 CONTRAINDICATIONS Rifinah is contraindicated in patients who are hypersensitive to rifamycins or isoniazid or any of the excipients (see section 6.1); the presence of jaundice; concurrent treatment with the combination of saquinavir/ritonavir (see section 4.5 Interaction with other medicinal products and other forms of interaction). 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Rifinah is a combination of 2 drugs, each of which has been associated with liver dysfunction. All tuberculosis patients should have pre-treatment measurements of liver function. Adults treated for tuberculosis with Rifinah should have baseline measurements of hepatic enzymes, bilirubin, serum creatinine, a complete blood count and a platelet count (or estimate). Patients should be seen at least monthly during therapy and should be quest Lire le document complet